PSAPP mice exhibit regionally selective reductions in gliosis and plaque deposition in response to S100B ablation

Journal of Neuroinflammation

Volumn 7, Issue , 2010, Pages

  Roltsch, Emily ^a   Holcomb, Leigh ^b,c   Young, Keith A ^b,c   Marks, Alexander ^d   Zimmer, Danna B ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN PROTEIN; CELL PROTEIN; CONGO RED; GLIAL FIBRILLARY ACIDIC PROTEIN; PROTEIN APP; PROTEIN IBAI; PROTEIN PS 1; PROTEIN S100B; TAU PROTEIN; UNCLASSIFIED DRUG; AIF1 PROTEIN, MOUSE; CALCIUM BINDING PROTEIN; NERVE GROWTH FACTOR; PROTEIN S 100; S 100 CALCIUM BINDING PROTEIN BETA SUBUNIT; S-100 CALCIUM-BINDING PROTEIN BETA SUBUNIT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BRAIN REGION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; GLIOSIS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOUSE; MOUSE STRAIN; NEUROPATHOLOGY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; AMYLOID PLAQUE; ANIMAL; BRAIN CORTEX; CYTOLOGY; DISEASE MODEL; GENETICS; HIPPOCAMPUS; HUMAN; METABOLISM; MICROGLIA; MOUSE MUTANT; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; ASTROCYTES; CALCIUM-BINDING PROTEINS; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOSIS; HIPPOCAMPUS; HUMANS; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROGLIA; NERVE GROWTH FACTORS; NEURONS; PLAQUE, AMYLOID; S100 PROTEINS; TAU PROTEINS;

EID: 78149492695     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-7-78     Document Type: Article

References (72)

1. Zimmer DB, Chaplin J, Baldwin A, Rast M. S100-mediated signal transduction in the nervous system and neurological diseases. Cell Mol Biol 2005, 51:201-214.
2. Mrak RE, Griffin WS. Trisomy 21 and the brain. J Neuropathol Exp Neurol 2004, 27:512-518.
3. Van Eldik LJ, Wainwright MS. The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain. Restor Neurol Neurosci 2003, 21:97-108.
4. Moore BW. A soluble protein characteristic of the nervous system. Biochem Biophys Res Comm 1965, 19:739-744. 10.1016/0006-291X(65)90320-7, 4953930.
5. Zimmer DB, Sadosky PW, Weber D. Molecular mechanisms of S100-target protein interactions. Microscopy Res Technique 2003, 60:552-559.
6. Zimmer DB, Weber DJ. The calcium dependent interaction of S100B with its protein targets. Cardiovasc Psychiatry Neurol 2010, 2933916, 20827422.
7. Hoffman MA, Srury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Meurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999, 97:889-910. 10.1016/S0092-8674(00)80801-6, 10399917.
8. Leclerc E, Sturchler E, Vetter SW. The S100B/RAGE axis in alzheimer's disease. Cardiovasc Psychiatry Neurol 2010, 2905692, 20672051.
9. Hu J, Castets F, Buevara JL, Van Eldik LJ. S100β stimulates inducible nitric oxide synthase activity and mRNA levels in rat cortical astrocytes. J Biol Chem 1996, 271:2543-2547. 10.1074/jbc.271.5.2543, 8576219.
10. Pena LA, Brecher CW, Marshak DR. β-amyloid regulates gene expression of glial trophic substance S100β in C6 glioma and primary astrocyte cultures. Mol Brain Res 1995, 34:118-126. 10.1016/0169-328X(95)00145-I, 8750867.
11. Pinto SS, Gottfried C, Mendez A, Goncalves D, Karl J, Goncalves CA, Wofchuk S, Rodnight R. Immunocontent and secretion of S100B in astrocyte cultures from different brain regions in relation to morphology. FEBS Lett 2002, 486:, 203-207.
12. Whitaker-Azmitia PM, Murphy R, Azmitia EC. Stimulation of astroglial 5-HT1A receptors releases the serotonergic growth factor, protein S-100, and alters astroglial morphology. Brain Res 1990, 528:155-158. 10.1016/0006-8993(90)90210-3, 2245332.
13. Tramontina F, Tramontina AC, Souza DF, Leite MC, Gottfried C, Souza DO, Wofchuk ST, Goncalves CA. Glutamate uptake is stimulated by extracellular S100B in hippocampal astrocytes. Cell Mol Neurobiol 2006, 26:81-86.
14. Quincozes-Santos A, Rosa RB, Leipnitz G, de Souza DF, Seminotti B, Wajner M, Goncalves CA. Induction of S100B secretion in C6 astroglial cells by the major metabolites accumulating in glutaric acidemia type 1. Metab Brain Dis 2010, 25:191-198. 10.1007/s11011-010-9203-0, 20437086.
15. Nogueira MI, Abbas SY, Campos LGM, Allemandi W, Lawson P, Takada SH, Azimitia EC. S100B protein expression: gender and age-related daily changes. Neurochem Res 2009, 34:1355-1362. 10.1007/s11064-009-9915-x, 19205880.
16. Sorci G, Bianchi R, Riuzzi F, Tubaro C, Arcuri C, Giambanco I, Donato R. S100B protein, a damage-associated molecular pattern protein in the brain and heart, and beyond. Cardiovasc Psychiatry Neurol 2010, 2933911, 20827421.
17. Mori T, Asano T, Town T. Targeting S100B in cerebral ischemia and in alzheimer's disease. Cardiovasc Psychiatry Neurol 2010, 2939387, 20862385.
18. Demuro A, Parker I, Stutzmann GE. Calcium signaling and amyloid toxicity in Alzheimer disease. J Biol Chem 2010, 285:12463-12468. 10.1074/jbc.R109.080895, 20212036.
19. Supnet C, Bezprozvanny I. The dysregulation of intracellular calcium in Alzheimer disease. Cell Calcium 2010, 4:183-189.
20. Querfurth HW, LaFerla FM. Alzheimer's disease. New England J Med 2010, 362(3):29-344.
21. Small SA, Duff K. Linking Aβ and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008, 60:534-5542. 10.1016/j.neuron.2008.11.007, 2692134, 19038212.
22. Marshak DR, Pesce SA, Stanley LC, Griffin WS. Increased S100 beta neurotrophic activity in Alzheimer's disease temporal lobe. Neurobiol Aging 1992, 13:1-7. 10.1016/0197-4580(92)90002-F, 1371849.
23. Van Eldik LJ, Griffin WST. S100β expression in Alzheimer's disease: relation to neuropathology in brain regions. Biochim Biophys Acta 1994, 1223:398-403. 10.1016/0167-4889(94)90101-5, 7918676.
24. Chaves ML, Camozzato AL, Ferreira ED, Piazenski I, Kochhann R, Dall'Igna O, Mazzini GS, Souza DO, Portela LV. Serum levels of S100B and NSE proteins in Alzheimer's disease patients. J Neuroinflamm 2010, 7:6.
25. Lambert J-C, Ferreira S, Gussekloo J, Christiansen L, Brysbaert G, Slagboom E, Cottel D, Petit T, Hauw J-J, DeKosky ST, Richard F, Berr C, Lendon C, Kamboh MI, Mann D, Christensen K, Westendorp R, Amouyel P. Evidence for the association of the S100B gene with low cognitive performance and dementia in the elderly. Mol Psychiatry 2007, 12:870-880. 10.1038/sj.mp.4001974, 17579612.
26. Mori T, Koyama N, Arendash GW, Horikoshi-Sakuraba Y, Tan J, Towne T. Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the TG2576 mouse model of Alzheimer's disease. GLIA 2010, 58:300-314.
27. Anderson PBJ, Watts HR, Jen S, Gentleman SJ, Moncaster JA, Walsh DT, Jen L-S. Differential effect of interleukin-1β and S100B on amyloid precursor protein in rat retinal neurons. Clin Opthamol 2009, 3:235-242.
28. Esposito G, Scuderi C, Lu J, Savani C, De Filippis D, Iuvone T, Steardo L, Sheen V, Steardo L. S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells. J Cell Mol Med 2008, 12:914-927. 10.1111/j.1582-4934.2008.00159.x, 18494933.
29. Chow S-K, Yu D, MacDonald CL, Buibas M, Silva BA. Amyloid-β directly induces spontaneous calcium transients, delayed intercellular calcium waves, and gliosis in rat cortical astrocytes. ASN Neuro 2010, 2. art:e00026, 10.1042/AN20090035, 2810812, 20001968.
30. Sen J, Belli A. S100B in neuropathologic states: the CRP of the brain?. J Neurosci Res 2007, 85:1373-1380. 10.1002/jnr.21211, 17348038.
31. Friend WC, Clapoff S, Landry C, Belcker LE, O'Hanlon D, Allore RJ, Brown IR, Marks A, Roder J, Dunn RJ. Cell-specific expression of high levels of human S100 beta in transgenic mouse brain is dependent on gene dosage. J Neurosci 1992, 12:4337-4346.
32. Craft JM, Watterson DM, Marks A, Van Eldik LJ. Enhanced susceptibility of S-100B transgenic mice to neuroinflammation and neuronal dysfunction induced by intracerebroventricular infusion of human beta-amyloid. GLIA 2005, 51:209-216. 10.1002/glia.20194, 15810011.
33. Mori T, Town T, Tan J, Yada N, Horikoshi Y, Yamamoto J, Shimoda T, Tateishi N, Asano T. Arundic acid ameliorates cerebral amyloidosis and gliosis in Alzheimer transgenic mice. J Pharmacol Exp Ther 2006, 318:571-578. 10.1124/jpet.106.105171, 16709678.
34. Markowitz J, MacKerell AD, Weber DJ. A search for inhibitors of S100B, a member of the S100 family of calcium-binding proteins. Mini Rev Med Chem 2007, 7:609-616. 10.2174/138955707780859422, 17584159.
35. Holcomb LA, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Sright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998, 4:97-100. 10.1038/nm0198-097, 9427614.
36. Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan DG. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: Lack of association with amyloid deposits. Behavior Genet 1999, 29:177-185.
37. Gordon MN, King DL, Diamond DM, Jantzen PT, Boyett KV, Hope CE, Hatcher JM, DiCarlo G, Gottschall WP, Morgan D, Arendash GW. Correlation between cognitive deficits and Aβ deposits in transgenic APP+PS1 mice. Neurobiol Aging 2001, 22:377-385. 10.1016/S0197-4580(00)00249-9, 11378242.
38. Gordon MN, Holcomb LA, Jantzen P, DiCarlo G, Connor K, Melachrino J, O'Callaghan J, Morgan D. Time course of the development of Alzheimer-like pathology in the doubly transgenic mPS1+mAPP mouse. Exp Neurol 2002, 173:183-195. 10.1006/exnr.2001.7754, 11822882.
39. Xiong Z, O'Hanlon D, Becker LE, Roder J, MacDonald JF, Marks A. Enhanced calcium transients in glial cells in neonatal cerebellar cultures derived from S100B null mice. J Exp Cell Res 2000, 257:281-289.
40. Hou Y, Zhu E, Rrapo J, Tian M, Takashi D, Commins E, He SJ, Fernandez F, Tan J. HIV-1 Tat contributes to alzheimer's disease-like pathology in PSAPP mice. Int J Clin Exp Pathol 2009, 2:433-443. 2655152, 19294002.
41. Ricobaraza A, Cuadrado-Tejedor M, Perez-Mediavilla A, Frechilla D, Del Rio J, Garcia-Osta A. Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology 2009, 34:1721-32. 10.1038/npp.2008.229, 19145227.
42. Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Lhnishi K, Ishibashi K, Teraoka R, Sakama N, Yamashita T, Nishitsuji K, Ito K, Shimada H, Lambert MP, Klein WL, Mori H. A mouse model of amyloid β oligomers: Their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci 2010, 30:4845-4856. 10.1523/JNEUROSCI.5825-09.2010, 20371804.
43. Sheng JG, Mrak RE, Rovnaghi CR, Kozlowska E, Van Eldik LJ, Griffin WST. Human brain S100b and S100b mRNA expression increases with age: pathogenic implications for Alzheimer's disease. Neurobiol Aging 1996, 17:359-363. 10.1016/0197-4580(96)00037-1, 8725896.
44. Nishiyama H, Knopfel T, Endo S, Itohara S. Glial S100B modulates long-term neuronal synaptic plasticity. Proc Natl Acad Sci, USA 2002, 99:4037-4042.
45. Sakatini S, Seto-Ohshima A, Itohara S, Hirase H. Impact of S100B on local field potential patterns in anesthetized and kainic acid-induced seizure conditions in vivo. Eur J Neurosci 2007, 25:1144-1154. 10.1111/j.1460-9568.2007.05337.x, 17331210.
46. Sakatani S, Seto-Ohshima A, Shinohara Y, Yamamoto Y, Yamamoto H, Itohara S, Hirase H. Neural-activity-dependent release of S100B from astrocytes enhances kainate-induced gamma oscillations in vivo. J Neurosci 2008, 28:10928-10936. 10.1523/JNEUROSCI.3693-08.2008, 18945900.
47. Schulte-Herbruggen O, Hortnagl H, Ponath G, Rothermundt M, Hellweg R. Distinct regulation of brain-derived neurotrophic factor and noradrenaline in S100B knockout mice. Neurosci Letters 2008, 442:100-103.
48. Gomez-Isla T, Price JL, McKeel DW, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild alzheimer's disease. J Neurosci 1996, 16:4491-4500.
49. Romito-Diiacomo RR, Menegay H, Cicero SA, Herrup K. Effects of Alzheimer's disease on different cortical layers: the role of intrinsic differences in Aβ susceptibility. J Neurosci 2007, 27:8496-8504. 10.1523/JNEUROSCI.1008-07.2007, 17687027.
50. Hyman BT, Van Hoesen GW, Damasio AR, Barnes DL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 1984, 225:1168-1170. 10.1126/science.6474172, 6474172.
51. Asano T, Mori T, Shimoda T, Shinagawa R, Satoh S, Yada N, Katsumata S, Matsuda S, Kagamiishi Y, Tateishi N. Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B. Curr Drug Targets CNS Neurol Disord 2005, 4:127-142. 10.2174/1568007053544084, 15857298.
52. Perry VH, Nicoll JAR, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol 2010, 4:193-201.
53. Morgan D. Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice. Neurochem Int 2006, 49:190-194. 10.1016/j.neuint.2006.03.017, 16740342.
54. Heneka MT, Nadrigny F, Regen T, Martinez-Hernanadez A, Dumitrescu-Ozimek L, Terwel D, Jardanhazi-Kurutz D, Walter J, Kirchhoff F, Hanisch UK, Kummer MP. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci, USA 2010, 107:6058-6063.
55. Fuhrmann M, Bittner T, Jung CK, Burgold S, Page RM, Mitteregger G, Haass C, LaFerla FM, Kretzschmar H, Herms J. Microglial Cs3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat Neurosci 2010, 13:411-413. 10.1038/nn.2511, 20305648.
56. Lee CY, Landreth GE. The role of microglia in amyloid clearance from the AD brain. J Neural Transm 2010, 117(8):949-60. 10.1007/s00702-010-0433-4, 20552234.
57. Rebaudo R, Melani R, Balestrino M, Cupello A, Haglid K, Hyden H. Antiserum against S-100 protein prevents long term potentiation through a cAMP-related mechanism. Neurochem Res 2000, 25:541-545. 10.1023/A:1007524412366, 10823588.
58. Fulle S, Pietrangelo T, Mariggio MA, Lorenzon P, Racanicchi L, Mozizymas J, Guarnieri S, Zuffoni-Grassi G, Fano G. Calcium and fos involvement in brain-derived Ca(2+)-binding protein (S100)-dependent apoptosis in rat phaeochromacytoma cells. Exptl Physiol 2000, 85:243-253.
59. Hoppman S, Steinback J, Pietzsch J. Scavenger receptors are associated with cellular interaction of S100A12 in vitro and in vivo. Intl J Biochem Cell Biol 2010, 42:651-661.
60. Perrone L, Peulso G, Lenone M. RAGE recycles at the plasma membrane in S100B secretory vesicles and promotes Schwann cells morphological changes. J Cell Physiol 2008, 217:60-71. 10.1002/jcp.21474, 18452184.
61. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996, 382:685-691. 10.1038/382685a0, 8751438.
62. Takeuchi M, Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharmaceut Design 2008, 14:973-978.
63. Deane R, Zlokovic BV. Role of the blood-brain-barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2007, 4:191-197. 10.2174/156720507780362245, 17430246.
64. Yan SD, Bierhaus A, Nawroth PP, Stern DM. RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation. J Alzheimers Dis 2009, 16:833-843.
65. Steiner J, Walter M, Guest P, Myint AM, Schiltz K, Panteli B, Brauner M, Bernstein H-G, Gos T, Herberth M, Schroeter JL, Schwartz MJ, Westphal S, Bahn S, Bogerts B. Elevated S100B levels in schizophrenia are associated with insulin resistance. Mol Psychiatry 2010, 15:3-4. 10.1038/mp.2009.87, 20029405.
66. Steiner J, Schroeter ML, Schiltz K, Bernstein H-G, Muller UJ, Richter-Landsberg C, Muller WE, Walter M, Gos T, Bogerts B, Keilhoff G. Haloperidol and clozapine decrease S100B release from glial cells. Neurosci 2010, 167:1025-1031.
67. Pham N, Fazio V, Cucullo L, Teng Q, Biberthaler P, Bazarian JJ, Janigro D. Extracranial sources of S100B do not affect serum levels. PLoS One 2010, 5(9). 10.1371/journal.pone.0012691, 2937027, 20844757.
68. Shepherd CE, Goyette J, Utter V, Rahimi F, Geczy CL, Halliday GM. Inflammatory S100A9 and S100A12 proteins in alzheimer's disease. Neurobiol Aging 2006, 27:1554-1563. 10.1016/j.neurobiolaging.2005.09.033, 16253391.
69. Boom A, Pochet R, Authelet M, Pradier L, Borghgraef P, Van Leuven F, Heizmann CW, Brion J-P. Astrocytic calcium/zinc binding protein S100A6 over expression in alzheimer's disease and in PS1/APP transgenic mice models. Biochim Biophys Acta 2004, 1742:161-168. 10.1016/j.bbamcr.2004.09.011, 15590066.
70. Qin W, Ho L, Wang J, Peskink E, Pasinetti GM. S100A7, a novel alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10. PLoS ONE 2009, 4:e4183. 10.1371/journal.pone.0004183, 2613557, 19159013.
71. Nedergaard M, Rodriguez JJ, Verkhratsky A. Glial calcium and disease of the nervous system. Cell Calcium 2010, 47:140-149. 10.1016/j.ceca.2009.11.010, 20045186.
72. Matute C. Calcium dyshomeostasis in white matter pathology. Cell Calcium 2010, 47:150-157. 10.1016/j.ceca.2009.12.004, 20036774.